The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $2.12 in the prior trading day, Humacyte Inc (NASDAQ: HUMA) closed at $2.09, down -1.42%. In other words, the price has decreased by -$1.42 from its previous closing price. On the day, 1.43 million shares were traded. HUMA stock price reached its highest trading level at $2.1752 during the session, while it also had its lowest trading level at $2.09.
Ratios:
Our goal is to gain a better understanding of HUMA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.28 and its Current Ratio is at 3.68. In the meantime, Its Debt-to-Equity ratio is 2.28 whereas as Long-Term Debt/Eq ratio is at 2.15.
On December 20, 2024, H.C. Wainwright reiterated its Buy rating and also lowered its target price recommendation from $12 to $15.
On December 11, 2023, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $6.H.C. Wainwright initiated its Buy rating on December 11, 2023, with a $6 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 14 ’25 when Scheessele William John bought 6,493 shares for $1.54 per share. The transaction valued at 9,999 led to the insider holds 22,018 shares of the business.
Sander Dale A. bought 20,000 shares of HUMA for $30,600 on Apr 10 ’25. The CFO and Chief Corp. Deve. Off. now owns 40,600 shares after completing the transaction at $1.53 per share. On Apr 10 ’25, another insider, Parikh Shamik J, who serves as the Chief Medical Officer of the company, bought 7,500 shares for $1.55 each. As a result, the insider paid 11,625 and bolstered with 7,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HUMA now has a Market Capitalization of 324198720 and an Enterprise Value of 343863328. For the stock, the TTM Price-to-Sale (P/S) ratio is 623.45 while its Price-to-Book (P/B) ratio in mrq is 8.99. Its current Enterprise Value per Revenue stands at 665.113 whereas that against EBITDA is -3.314.
Stock Price History:
The Beta on a monthly basis for HUMA is 1.91, which has changed by -0.59099805 over the last 52 weeks, in comparison to a change of 0.12632763 over the same period for the S&P500. Over the past 52 weeks, HUMA has reached a high of $9.79, while it has fallen to a 52-week low of $1.15. The 50-Day Moving Average of the stock is 2.71%, while the 200-Day Moving Average is calculated to be -43.34%.
Shares Statistics:
The stock has traded on average 4.55M shares per day over the past 3-months and 2505200 shares per day over the last 10 days, according to various share statistics. A total of 155.12M shares are outstanding, with a floating share count of 125.45M. Insiders hold about 19.13% of the company’s shares, while institutions hold 39.88% stake in the company. Shares short for HUMA as of 1749772800 were 28426146 with a Short Ratio of 6.25, compared to 1747267200 on 30350872. Therefore, it implies a Short% of Shares Outstanding of 28426146 and a Short% of Float of 21.100001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
